Navigation Links
Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
Date:9/5/2007

Barcelona Hosts Key Investigator Meeting for European Participants in Phase

3 AGENDA Trial Targeting Biomarker-Defined Population

BERKELEY HEIGHTS, N.J., Sept. 5 /PRNewswire-FirstCall/ - Genta Incorporated (Nasdaq: GNTA) announced that data from the Company's Phase 3 trial of Genasense(R) (oblimersen sodium) plus chemotherapy would be presented at the opening session of the first Worldwide Melanoma Center Meeting organized by the European Association of Dermato-Oncology (EADO). Genta, which is a Silver Level sponsor of the EADO meeting, will also host its key investigator meeting for European participants in the Company's ongoing Phase 3 trial of Genasense in advanced melanoma. The Genasense clinical results will be presented by Dr. Claus Garbe, who is Chair of the Congress, and Professor of Dermatology and Head of the Division of Dermatooncology, Department of Dermatology, University Medical Center, Tubingen, Germany. The EADO, which is the lead international cooperative group for the current Phase 3 trial, is meeting this week in Barcelona, Spain.

The new Genasense trial, known as AGENDA, is a randomized, double-blind, placebo-controlled study in which patients are randomly assigned to receive Genasense plus dacarbazine (DTIC) or DTIC alone. AGENDA is designed to confirm the safety and efficacy of Genasense when combined with DTIC in patients who have not previously received chemotherapy. The trial will accrue approximately 300 patients who have been defined using a biomarker and will be conducted at approximately 100 sites worldwide, including North America, Europe and Australia. Patient enrollment into AGENDA has been initiated.

About Genasense in Advanced Melanoma

Genasense, Gent
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
2. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
3. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
4. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
5. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
6. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
7. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
8. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... of the "Prescription Pain Drugs - Including ... - Global Markets, Competitors and Opportunities: 2015 - ... offering. Pain is defined as ... actual or potential tissue damage. At some point, ...
(Date:8/29/2015)... 29, 2015 La sofisticada ... los sistemas de imagen por Ultrasonidos   ofrece resultados ... examen rápidos y un flujo de trabajo   optimizado, ... el proceso de detección de Cardiopatías   ... hoy el lanzamiento europeo de HeartModel A.I ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
Breaking Medicine Technology:Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5CytomX Files Registration Statement for Proposed Initial Public Offering 2
(Date:8/31/2015)... , ... September 01, 2015 , ... The PT Outcomes ... clinically relevant measures for physical therapy patients. The Registry is being developed by the ... Inc. stated "We are happy to be selected to contribute FOTO Outcomes measures as ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... released their latest predictive use case focused on helping hospital perform under the ... this program, hospital payments are adjusted based on performance across four domains related ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... in giving potential patients the resources they need to have a successful cosmetic ... board certified plastic surgeons; Cosmetic Town Journal is always ready to help. , ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... at Western University of Health Sciences to learn more about its integrated approach ... of Dental Sciences and Institute of Cellular Medicine at Newcastle University, and Susan ...
(Date:8/31/2015)... ... ... to undergoing a hair transplant, most patients have donor hair moved from one part of ... on top of the scalp, as well as filling in areas missing hair, is a ... areas of their head. , What about patients who have a limited, or even depleted, ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2
... Ill. -- A growing number of health research programs ... groups help recruit study participants, obtain informed consent, collect ... But existing programs that educate researchers, community groups ... meet the needs of all groups that have a ...
... 2012 A new study finds differences in screening ... in colorectal cancer incidence and nearly 20 percent of ... stage-specific survival, which likely reflect differences in treatment account ... cancer mortality rates. The study, appearing early online in ...
... WEDNESDAY, May 2 (HealthDay News) -- Finding out who the ... emergence of a simple blood test for women that can ... The paternity screening, developed at a private biotech company in ... are done later in the pregnancy, its developer says. ...
... increases the life expectancy of men by 6.2 years and ... Copenhagen City Heart study presented at the EuroPRevent2012 meeting. ... Peter Schnohr told delegates that the study,s most recent analysis ... of jogging per week at a "slow or average" ...
... is currently the leading cause of pregnancy-related deaths during ... publication in The Endocrine Society,s Journal of Clinical ... adrenomedullin (ADM) may help predict this condition. TEP ... the fallopian tubes instead of in the uterus. In ...
... women aged 40-49 diagnosed with breast cancer on screening mammography report ... conducted at Elizabeth Wende Breast Care, LLC in Rochester, NY of ... out of 373 cancers (61%) were found in women, aged 40-49 ... the 228 patients did have a prior personal history of breast ...
Cached Medicine News:Health News:Better ethics education needed in community-based research 2Health News:Study says screening accounts for much of black/white disparity in colorectal cancer 2Health News:Who's the Dad? First-Trimester Blood Test May Tell 2Health News:Who's the Dad? First-Trimester Blood Test May Tell 3Health News:Regular jogging shows dramatic increase in life expectancy 2Health News:Regular jogging shows dramatic increase in life expectancy 3Health News:Hormone may help predict tubal ectopic pregnancy 2
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... only catheter of its kind, the ... collects real-time cardiac electrical information, translating ... With 64 electrodes, this unique tool ... than 3,000 points of electrical data ...
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
Medicine Products: